Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone

Diabetologia

Volumn 41, Issue 5, 1998, Pages 569-576

  Tack, C J J ^a,b   Ong, M K E ^a   Lutterman, J A ^a   Smits, P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Endothelial function; Insulin resistance; Insulin sensitisers; Obesity; Troglitazone; Vasodilatation

Indexed keywords

ACETYLCHOLINE; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN ALBUMIN; INSULIN; N(G) METHYLARGININE; NEUTRAL INSULIN; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; PLACEBO; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEAN BODY WEIGHT; MALE; OBESITY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ACETYLCHOLINE; ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR SYSTEM; CASE-CONTROL STUDIES; CHROMANS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FASTING; FEMALE; FOREARM; GLUCOSE CLAMP TECHNIQUE; HEMODYNAMIC PROCESSES; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; NITROPRUSSIDE; OBESITY; OMEGA-N-METHYLARGININE; REFERENCE VALUES; REGIONAL BLOOD FLOW; THIAZOLES; THIAZOLIDINEDIONES; VASODILATION; VASODILATOR AGENTS;

EID: 0031977203     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050948     Document Type: Article

References (39)

1. Dinneen S, Gerich J, Rizza R (1992) Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 327: 707-713
2. Anderson EA, Hoffmann RP, Balon TW. Sinkey CA, Mark AL (1991) Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87: 2246-2252
3. Baron AD, Brechtel-Hook G, Johnson AD, Hardin D (1993) Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 21: 129-135
4. Tack CJJ, Smits P, Willemsen JJ, Lenders JWM, Thien T, Lutterman JA (1996) Effects of insulin on vascular tone and sympathetic nervous system in NIDDM. Diabetes 45: 15-22
5. Baron AD (1996) The coupling of glucose metabolism and perfusion in human skeletal muscle. Diabetes 45(S1): 105-109
6. Laakso M, Edelman SV, Brechtel G, Baron AD (1990) Decreased effect of insulin to stimulate skeletal blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85: 1844-1852
7. Laakso M, Edelman SV, Brechtel G, Baron AD (1992) Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41: 1076-1083
8. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P (1995) Nitric oxide release accounts for insulin's effects in humans. J Clin Invest 94: 2511-2515
9. Steinberg HM, Brechtel G, Johnson A, Fineherg N, Baron AD (1994) Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric-oxide release. J Clin Invest 94: 1172-1179
10. McVeigh GE, Brennan GM, Johnston GD et al. (1992) Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35: 771-776
11. Cohen RA (1993) Dysfunction of vascular endothelium in diabetes mellitus. Circulation 87 (Suppl V):V67-V76
12. Panza JA, Quyyumi AA, Brush JE, Epstein SE (1990) Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323: 22-27
13. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD (1996) Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 97:2601-2610
14. Saltiel AR, Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669
15. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15: 193-203
16. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-1193
17. Ghazzi MN, Perez JE, Antonucci TK et al. (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46: 433-439
18. Brakkee AJM, Vendrik AJH (1966) Strain gauge plethysmography, theoretical and practical notes on a new design. J Appl Physiol 21: 701-704
19. Willemsen JJ, Ross HA, Jacobs MC et al. (1995) Highly sensitive and specific HPLC with fluorometric detection for determination of plasma epinephrine and norepinephrine applied to kinetic studies in humans, Clin Chem 41: 1455-1460
20. Dillon RS (1965) Importance of hematocrit in interpretation of blood sugar. Diabetes 14: 672-674
21. Bergman RN, Finegood DT, Ader M (1985) Assessment of insulin sensitivity in vivo. Endocr Rev 6: 245-285
22. Hills M, Armitage P (1979) The two-period crossover clinical trial. Br J Pharmacol 8: 7-20
23. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D (1995) Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 25: 918-923
24. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P, Scherrer U (1994) Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 93: 2365-2371
25. Baron AD, Laakso M, Brechtel G, Edelman SV (1991) Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in non-insulin-dependent diabetic subjects. Effects of insulin therapy. J Clin Invest 87: 1186-1194
26. Rocchini AP, Moorehead C, Katch V, Key J. Finta KM (1992) Forearm resistance vessel abnormalities and insulin resistance in obese adolescents. Hypertension 19:616-620
27. Petrie JR, Ueda S, Webb DJ, Elliot HL, Connell JMC (1996) Endothelial nitric oxide production and insulin sensitivity. Circulation 93: 1331-1333
28. Utriainen T, Mäkimattila S, Virkamäki A, Bergholm R, Yki-Järvinen H (1996) Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. Diabetologia 39: 1477-1482
29. Natali A, Taddei S, Quiñones Galvan A, et al. (1997) Insulin sensitivity, vascular reactivity and clamp-induced vasodilation in essential hypertension. Circulation 96: 849-855
30. G-monomethyl-L-Arg reduces the forearm vasodilator response to acelylcholine but not to methacholine in humans. J Cardiovasc Pharmacol 22: 884-888
31. Mäkimattila S, Virkamaki A, Groop PH et al. (1996) Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 94: 1276-1282
32. Avagaro A, Piarulli F, Valerio A et al. (1997) Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes 46: 1040-1046
33. Chowienczyk PJ, Watts GF, Cockcroft J, Ritter JM (1992) Impaired endothelium-dependent vasodilalion of forearm resistance vessels in hypercholesterolaemia. Lancet 340: 1430-1432
34. Karhapää P, Voutilainen E, Kovanen PT, Laakso M (1993) Insulin resistance in familial and nonfamilial hypercholesterolemia. Arteriosclerosis and Thrombosis 13: 367-370
35. McKay MK, Hester RL (1996) Role of nitric oxide, adenosine. and ATP-sensitive potassium channels in insulin-induced vasodilation. Hypertension 28: 202-208
36. Tack CJJ, Lutterman JA, Vervoort G, Thien T, Smits P (1996) Activation of the sodium-potassium pump contributes to insulin-induced vasodilation in humans. Hypertension 28: 426-432
37. Rosetti L, Giaccari A, DeFronzo RA (1990) Glucose toxicity. Diabetes Care 13: 610-630
38. Reaven GM (1993) Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 44: 131-141
39. Mimura K, Umeda F, Hiramata S et al. (1994) Effects of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11: 685-691